Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
Holding IMUX?
Track your performance easily
IMUX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.97 - $2.11
Previous CloseN/A
Volume261.21K
Average Volume (3M)870.14K
Market Cap
$88.84M
Enterprise Value$108.93M
Total Cash (Recent Filing)$59.99M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Feb 20, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding90,079,020
10 Day Avg. Volume935,650
30 Day Avg. Volume870,138
Standard Deviation0.23
R-Squared0.18
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$12.25Price Target Upside1137.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Immunic News
PremiumCompany Announcements
Immunic, Inc. Advances MS Trials Amid Financial Update
PremiumPre-Earnings
Is IMUX a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Efficacy And DifferentiationIncreased confidence in vidofludimus calcium, bringing a differentiated approach to treating the full MS spectrum, including both relapsing and progressive forms.
Regulatory And Trial ProgressThe strategic design of the trials to evaluate vido versus placebo rather than an active comparator puts the company in the best case scenario to gain regulatory approval.
Safety And AdministrationVidofludimus calcium combines the best aspects of teriflunomide and BTK inhibitors into one easily administered oral formulation, requiring no burdensome screening or monitoring.
Bears Say
Financial PerformanceResearch and development expenses were higher than expected, potentially impacting financial projections.
Market CompetitionThe opportunity in relapsing multiple sclerosis is seen as having a more crowded commercial landscape, which may limit potential upside.
Regulatory ChallengesBTK inhibitors face challenges due to past failures and tolerability concerns, which cloud their path to regulatory success.
---
Ownership Overview
9.12% Insiders
6.34% Mutual Funds
0.09% Other Institutional Investors
79.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.97 and its highest was $2.11 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $88.84M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Nov 07, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.218 by -$0.022.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.24.
How many shares outstanding does Immunic have?
Immunic has 90,079,020 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.218. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
---
Immunic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.25 (1137.37% Upside)
$12.25 (1137.37% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 118.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $99.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.80%
12-Months-Change
Fundamentals
Return on Equity
-216.24%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
---
IMUX Company Deck
---
IMUX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, including strengthened leadership, progress in key clinical trials, and potential market impact of vidofludimus calcium. However, challenges such as increased R&D expenses and net losses were also noted. The sentiment leans slightly positive due to the promising clinical trial results and potential market opportunities.Read More>---
IMUX Stock 12 Month Forecast
Average Price Target
$12.25
▲(1137.37% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Corbus Pharmaceuticals
―
Kiniksa Pharmaceuticals
―
Moleculin Biotech
―
Verastem
―
Best Analysts Covering IMUX
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-20.06%
reiterated a buy rating 11 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -20.06% per trade.
---